Home › Ulcerative Colitis › New York
Ulcerative Colitis clinical trials in New York
30 studies for Ulcerative Colitis are looking for participants at sites in New York.
Cities in New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- New York Gastroenterology Associates ( Site 0253), New York
RecruitingPhase 3
All ages · All sexes · Updated Oct 2, 2026 · NCT06651281Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Westchester Putnam Gastroenterology PC, Carmel
- Five Towns Gastroenterology, Cedarhurst
- IMIDeology, Elmhurst
- and 5 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Ellipsis Research Group, Brooklyn
- Smart Medical Research - Jackson Heights, Jackson Heights
- Pioneer Clinical Research NY, New York
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Albany
- Xencor Investigative Site, Rochester
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT06619990A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 037, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-002, Albany
- Site US-016, Rochester
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Intercity Gastroenterology, Fresh Meadows
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06979336A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Westchester Putnam Gastroenterology, Carmel
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- and 3 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT07196748A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Columbia University Medical Center, New York
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Sep 24, 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Digestive Disease Medicine of Central New York, Utica
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07186101A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Stony Brook University, Stony Brook
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- NYU Langone Health, New York
- Weill Cornell Medical College- New York Presbyterian Hospital, New York
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- MedTraits NY - Site Number: 8400045, Maspeth
- Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- New York Gastroenterology Associates - Site Number: 8400009, New York
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- New York Gastroenterology Associates, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07577856A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
- Fink Children's Ambulatory Care Center, New York
- Kimmel Pavilion - NYU Langone, New York
- NYU Grossman School of Medicine, New York
- and 4 more
RecruitingPhase 2
Ages 2 to 11 · All sexes · Updated Aug 24, 2026 · NCT07470879A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
- Columbia University Medical Center, New York
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 21, 2026 · NCT06636656An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- MedTraits NY - Site Number: 8400045, Maspeth
- Manhattan Clinical Research, LLC - Site Number: 8400069, New York
- NYU Langone Health - Site Number: 8400091, New York
- and 4 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Saratoga Schenectady Gastroenterology Associates, Burnt Hills
- NYU Langone Health, New York
- Cornell University, New York
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173BOOM-IBD2 Pivotal Clinical Trial
- Northwell Health North Shore University Hospital, Manhasset
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Recruiting
Ages 18 to 85 · All sexes · Updated Aug 6, 2026 · NCT06571669Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- New York University, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- NYU Langone Health, New York
- Lenox Hill Hospital, Northwell Health, New York
RecruitingObservational study
Ages 18 to 64 · All sexes · Updated Jul 9, 2026 · NCT06398626A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- New York Presbyterian Hospital, New York
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, New York
- Mirador Therapeutics Selected Site, Rochester
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
- State University of New York Upstate Medical University, Syracuse
Recruiting
Ages 18 to 85 · All sexes · Updated Jan 8, 2026 · NCT05987852Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
- Bausch Health Site 006, The Bronx
RecruitingPhase 4
Ages 5 to 17 · All sexes · Updated Sep 16, 2025 · NCT04314375Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- New York University, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2025 · NCT06750731From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.